Changing patterns of opioid agonist therapy prescribing in a network of specialised clinics providing care to people with opioid use disorder in Victoria, Australia, 2015 to 2023

被引:0
作者
Dawe, Joshua [1 ,2 ]
Wilkinson, Anna Lee [2 ,3 ,4 ]
Curtis, Michael [1 ,5 ]
Asselin, Jason [1 ]
Henderson, Charles [1 ,6 ]
Makoni, Eric [7 ]
Dietze, Paul [1 ,5 ]
Hellard, Margaret [1 ,3 ,4 ,8 ,9 ,10 ]
Stoove, Mark [1 ,3 ,11 ]
机构
[1] Burnet Inst, Dis Eliminat, Melbourne, Vic, Australia
[2] Univ Bristol, Global Epidemiol & Modelling Grp, Bristol, Avon, England
[3] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Australia
[4] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Australia
[5] Curtin Univ, Natl Drug Res Inst, Melbourne, Australia
[6] NSW Users & AIDS Assoc, Sydney, Australia
[7] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, Australia
[8] Alfred Hlth, Dept Infect Dis, Melbourne, Australia
[9] Monash Univ, Melbourne, Australia
[10] Univ Melbourne, Doherty Inst, Melbourne, Australia
[11] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Australia
关键词
buprenorphine; methadone; opiate substitution treatment; opioid agonist therapy; opioid dependence; DEPOT;
D O I
10.1111/dar.14049
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction Long-acting injectable buprenorphine (LAIB) reduces the frequency of contact with opioid agonist therapy (OAT) service providers. Limited data exist on OAT prescribing in Australia after the introduction of subsidised LAIB prescribing in September 2019. This ecological study describes trends in OAT prescribing between 2015 and 2023 across a network of primary care services in Victoria, Australia. Methods We utilised electronic medical records from 17 clinics in Victoria that provide services to people with opioid dependence to describe OAT prescribing patterns. We described the annual number and type (methadone, buprenorphine, LAIB) of OAT prescriptions issued, individuals prescribed, and individuals initiating OAT. Interrupted time series assessed changes in quarterly OAT prescribing following the introduction of LAIB. Results Between 2015 and 2023, the average annual number of OAT prescriptions issued, and the average number of recipients prescribed OAT were 47,648 and 6470, respectively. Between 2020 and 2023, the proportion of individuals initiating on LAIB increased from 7% (73/1078) to 31% (357/1146). There was increasing quarterly OAT prescribing before the introduction of LAIB, after which methadone and buprenorphine prescribing declined by 2.6% (CR 0.974; 95% CI 0.968-0.980) and 3.2% (CR 0.968; 95% CI 0.963-0.973), respectively. After being introduced, quarterly LAIB prescribing increased by 13.1% (CR 1.131; 95% CI 1.096-1.167). Discussion and Conclusions We found substantial changes in OAT prescribing patterns in Victoria between 2015 and 2023, with shifts away from oral methadone and sublingual buprenorphine to LAIB. Alongside ongoing monitoring of prescribing patterns, future research should assess how LAIB impacts patient health and social outcomes.
引用
收藏
页数:7
相关论文
共 19 条
  • [1] Australian Government. Department of Health and Aged Care, 2024, Pharmaceutical Benefits Scheme (PBS)
  • [2] Australian Institute of Health and Welfare, 2023, National opioid pharmacotherapy statistics annual data collection
  • [3] Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia
    Barnett, Anthony
    Savic, Michael
    Lintzeris, Nicholas
    Bathish, Ramez
    Arunogiri, Shalini
    Dunlop, Adrian J.
    Haber, Paul
    Graham, Robert
    Hayes, Vicky
    Lubman, Dan, I
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2021, 227
  • [4] Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022
    Bharat, Chrianna
    Chidwick, Kendal
    Gisev, Natasa
    Farrell, Michael
    Ali, Robert
    Degenhardt, Louisa
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2024, 123
  • [5] Department of Health, 2021, Policy for maintenance pharmacotherapy for opioid dependence (addendum)
  • [6] Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence
    Farrell, Michael
    Shahbazi, Jeyran
    Byrne, Marianne
    Grebely, Jason
    Lintzeris, Nicholas
    Chambers, Mark
    Larance, Briony
    Ali, Robert
    Nielsen, Suzanne
    Dunlop, Adrian
    Dore, Gregory J.
    McDonough, Michael
    Montebello, Mark
    Nicholas, Thomas
    Weiss, Rob
    Rodgers, Craig
    Cook, Jon
    Degenhardt, Louisa
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 100
  • [7] Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine
    Gilman, Mark
    Li, Li
    Hudson, Kerrie
    Lumley, Tara
    Myers, Georgia
    Corte, Camilla
    Littlewood, Richard
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 2123 - 2129
  • [8] Gowing L., 2014, National guidelines for medication-assisted treatment of opioid dependence, P38
  • [9] Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
    Larance, Briony
    Degenhardt, Louisa
    Grebely, Jason
    Nielsen, Suzanne
    Bruno, Raimondo
    Dietze, Paul
    Lancaster, Kari
    Larney, Sarah
    Santo, Thomas, Jr.
    Shanahan, Marian
    Memedovic, Sonja
    Ali, Robert
    Farrell, Michael
    [J]. ADDICTION, 2020, 115 (07) : 1295 - 1305
  • [10] The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysis
    Lintzeris, Nicholas
    Hayes, Victoria
    Dunlop, Adrian J.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2024, 220 (06) : 339 - 340